Nick Haining
@nickhaining
Followers
3K
Following
2K
Media
109
Statuses
1K
CSO and co-founder of @ArsenalBio via @DanaFarber, @broadinstitute, and @Merck. He/his.
Boston, MA
Joined October 2009
I’m lucky that I get to work with this team.
We are excited to announce our $325 million #SeriesC financing. This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines. We thank the new investors along with our existing investors for their
1
1
33
Proud to be one of said Braniacs! Looking forward to discussing our exciting work at #AACR2023
There’s some really awesome science going on at @ArsenalBio — come and meet the brainiacs building tomorrow’s cell therapy today at #AACR23
2
2
12
There’s some really awesome science going on at @ArsenalBio — come and meet the brainiacs building tomorrow’s cell therapy today at #AACR23
businesswire.com
ArsenalBio to share preclinical data at AACR on the use of integrated circuit T cells for the development of cell therapies for solid tumor cancers.
1
7
38
Well deserved award to a thoughtful and original scientist who has helped us all understand a lot about how T cells work and don’t work. Congrats @EJohnWherry !
We congratulate @EJohnWherry, of @PennMedicine on being recognized with the 2023 AACR-CRI Lloyd J. Old Award in Cancer Immunology. Learn more: https://t.co/5mNugSx8Ig
@CancerResearch
0
0
28
I’m so glad this experiment ended and was reported in my lifetime. Amazing.
3
4
85
Four years ago, the founders had a bunch of ideas on a whiteboard and not much else. Today, @ArsenalBio has dosed the first patient with AB-1015, an engineered autologous T cell therapy for ovarian cancer. Incredibly proud of what the Arsenal team has accomplished. Onwards.
The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development:
2
10
109
Be like Carl
0
0
8
Very interesting as usual, Rob.
0
1
10
Go Deb go! Well deserved award to @DebattamaSen We’re going to learn a lot about the wiring of T cells from the Sen lab.
Early-stage investigators proposed innovative high-impact research ideas for the @NIHDirector’s New Innovator Award. See the projects the awardees will pursue: https://t.co/hQPzaylGYO
#NIHHighRisk
1
0
23
Our latest paper is out in @NatImmunol. This work represents a years-long effort from @dubrot_j Peter Du, @kathleenbyates @sarahkatelr and others to identify immune evasion genes using in vivo #CRISPRscreens in mouse cancer models treated with ICB.
4
24
123
Delighted for the opportunity to collaborate with the rockstar team at Genentech and deploy Arsenal's tech stack to solve the biggest challenges in T cell therapy. This is going to be a lot of fun.
ArsenalBio will receive $70 million for a multi-year collaboration with Genentech to deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T-cells to advance next-generation cell therapies for cancer. https://t.co/SQO75MxAi5
#genentech
3
3
64
Grateful for this opportunity to keep raising the bar for better engineered T cell therapies for patients with cancer. Can't wait to share what we're building. @ArsenalBio
fiercebiotech.com
Arsenal Bio is jumping headfirst into the cell therapy arena, and its latest fundraising haul, backed in part by Bristol Myers Squibb, is making a significant splash. | Arsenal Bio is reeled in $220...
2
8
79
This is my favorite tweet in quite some time.
@TheBcellArtist I have made a twitter account to tell you how disappointed I am with you for this tweet.
1
0
43
Cogent analysis of decision-making around Covid boosters.
What should you do about COVID vaccine boosters? Should you wait until the fall for a BA.4/5 version? How often can you get boosted? A few thoughts here:
0
1
5
Having just spent 3 days at a #PICINetwork retreat, I think some of the most exciting and innovative work was presented by the scholars/early career scientists. The “kids” are alright.
0
1
25
Our CEO @KDrazan, MD, was featured in @_CellandGene this morning! Hear Ken’s take on ArsenalBio’s pioneering approach and role in the future of engineering CAR-T #celltherapies in the Q&A by @ErinHarris_1 here: https://t.co/8BRAzSnKVB
#EngineeredToCure
cellandgene.com
ArsenalBio is taking different approaches to gene editing, target selection, cell circuit engineering, and computation to reimagine dosing, delivery, persistence, and affordability of cell therapy....
0
2
5
Regardless about the generalizability of this finding I remain a firm proponent of snack-time.
We tend to schedule our day ignoring that the times are not the same. For a judge, parole rulings were found to be dependent on the time of day: a prisoner had nearly a 0% chance of getting parole just before lunch, but 65% for parole right after lunch. https://t.co/ZOW7WHuxOj
0
0
7